Immunome Appoints Sandra M. Swain to Board of Directors
25 Abril 2024 - 7:26AM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused
on developing first-in-class and best-in-class targeted cancer
therapies, today announced the appointment of Sandra M. Swain,
M.D., to its Board of Directors. Dr. Swain has over 30 years of
oncology clinical research experience and has served on both public
company and non-profit boards.
“Immunome is pleased to welcome Sandra to the Board of
Directors, especially given her extensive experience as a
successful clinical researcher,” stated Clay Siegall, PhD,
President and Chief Executive Officer of Immunome. “Her deep
understanding of oncology and patient care will add a valuable
perspective as we advance AL102 through Phase 3 and prepare
Investigational New Drug (IND) filings for IM-1021 and
IM-3050.”
“I am drawn to Immunome’s commitment to developing
transformative therapies that meaningfully improve patients’
lives,” remarked Dr. Swain. “Immunome’s promising pipeline,
talented team, and focus on patients offers a tremendous
opportunity to address unmet medical need. I look forward to
serving as a Board member and supporting Immunome’s important
mission.”
Dr. Swain has served as Associate Dean for Research Development
at Georgetown University Medical Center since 2016, and as
Professor of Medicine at Georgetown University Medical Center since
2007. She has also served as Vice President of Genetic Medicine at
MedStar Health, a not-for-profit healthcare system, since 2018. Dr.
Swain served on the board of directors of the American Society of
Clinical Oncology (ASCO) from 2008-2013 and was ASCO President
2012-13. Since 2007, Dr. Swain has served on the board of directors
for Conquer Cancer, the ASCO Foundation, including as treasurer of
the Executive Committee from 2016 to 2019 and on the Joint
Investment Committee from 2016 to 2018. Dr. Swain previously served
on the board of directors of Seagen Inc. from November 2022 until
its acquisition by Pfizer Inc. in December 2023. Dr. Swain holds an
M.D. from the University of Florida and a B.A. in Chemistry from
the University of North Carolina at Chapel Hill. Dr. Swain
completed a residency in Internal Medicine at Vanderbilt University
and a fellowship in Medical Oncology at the National Cancer
Institute, National Institutes of Health.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including small molecules, ADCs, RLTs and immunotherapies.
We believe that pursuing underexplored targets with appropriate
drug modalities leads to transformative therapies. Our proprietary
memory B cell hybridoma technology allows for the rapid screening
and functional characterization of novel antibodies and
targets.
For more information, visit www.immunome.com or follow us on
X/Twitter and LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). We use words such as
“advance,” “promising,” “opportunity,” “look forward,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions of the PSLRA.
These forward-looking statements include, but are not limited to,
statements regarding Immunome’s expectations regarding its ongoing
clinical trial for AL102 and preparation of IND filings for IM-1021
and IM-3050; the advancement of Immunome’s pipeline; the ability to
execute on Immunome’s mission; and other statements regarding
management’s intentions, plans, beliefs, expectations or forecasts
for the future. No forward-looking statement can be guaranteed, and
actual results may differ materially from those projected. Such
forward-looking statements are based on Immunome’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors. These factors include, but are not
limited to, the risk that Immunome will not be able to realize the
benefits of its strategic transactions, Immunome’s ability to grow
and successfully execute on its business plan, including the
development and commercialization of its pipeline; changes in the
applicable laws or regulations; the possibility that Immunome may
be adversely affected by other economic, market, business, and/or
competitive factors; the risk that regulatory approvals for
Immunome’s programs and product candidates are not obtained, are
delayed or are subject to unanticipated conditions; the risk that
pre-clinical data may not be predictive of clinical data; the risk
that interim results of a clinical trial do not necessarily predict
final results; potential delays in the commencement, enrollment and
completion of clinical trials and the reporting of data therefrom;
the risk that our product and development candidates fail to
achieve their intended endpoints; the complexity of numerous
regulatory and legal requirements that Immunome needs to comply
with to operate its business; the reliance on Immunome’s
management; the prior experience and successes of the Immunome’s
management team not being indicative of any future success;
uncertainties related to Immunome’s capital requirements and
Immunome’s expected cash runway; the failure to obtain, adequately
protect, maintain or enforce Immunome’s intellectual property
rights; and other risks and uncertainties indicated from time to
time described in exhibit 99.2 filed with Immunome’s Current Report
on Form 8-K with Securities and Exchange Commission (“SEC”) on
February 13, 2024, and in Immunome’s Annual Report on Form 10-K for
the year ended December 31, 2023, filed with the SEC on March 28,
2024, and in Immunome’s other filings with the SEC. Immunome
cautions that the foregoing list of factors is not exclusive and
not to place undue reliance upon any forward-looking statements
which speak only as of the date made. Moreover, Immunome operates
in a very competitive and rapidly changing environment. New risks
emerge from time to time. Except as required by law, Immunome does
not undertake any obligation to update publicly any forward-looking
statements for any reason after the date of this press release to
conform these statements to actual results or to changes in their
expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240425337881/en/
Max Rosett Interim Chief Financial Officer
investors@immunome.com
Immunome (NASDAQ:IMNM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Immunome (NASDAQ:IMNM)
Gráfica de Acción Histórica
De May 2023 a May 2024